Lipum (LIPUM.ST) Stock Analysis & AI Equity Report
Lipum (LIPUM.ST) overview
Lipum (LIPUM.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Lipum reported revenue of SEK 0m and operating profit of SEK -55.2m; the year-end share price was 12.00 SEK and market capitalisation was SEK 207m. Lipum is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lipum's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-03. Data will be refreshed during report generation.
About Lipum
Lipum AB (publ) is a clinical-stage biopharmaceutical company developing treatments for chronic inflammatory diseases. Its lead program, SOL-116, is a humanized monoclonal antibody designed to block BSSL, a target in the immune system, and is being studied primarily for rheumatoid arthritis. The company also evaluates other inflammatory diseases with unmet medical need.
Generate the Lipum report
Lipum is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Lipum and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.